A PHASE 1 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTIPLE ASCENDING DOSE STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF THE LIVER-SELECTIVE TR-BETA AGONIST VK2809 (MB07811) IN HYPERCHOLESTEROLEMIC SUBJECTS
| Autor: | Rochelle Hanley, Brian Lian, Steve Schoenfeld |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Agonist biology medicine.drug_class business.industry Thyroid Cytochrome P450 Pharmacology Prodrug 03 medical and health sciences 030104 developmental biology medicine.anatomical_structure Pharmacokinetics medicine biology.protein Cardiology and Cardiovascular Medicine Beta (finance) business Receptor Hormone |
| Zdroj: | Journal of the American College of Cardiology. 67:1932 |
| ISSN: | 0735-1097 |
| DOI: | 10.1016/s0735-1097(16)31933-7 |
| Popis: | Thyroid hormone is a key regulator of lipoprotein metabolism, particularly acting via the beta isoform of nuclear T3 receptor in liver. VK2809 is a small molecule prodrug of a potent thyroid beta agonist. VK2809 is selectively cleaved in hepatic tissue by the action of cytochrome P450 isozyme 3A4 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|